UK Markets close in 3 mins

ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Immix Biopharma Inc (NASDAQ: IMMX) announced positive interim data from an animal study in Soft Tissue Sarcoma (STS).

  • STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves).

  • After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for trabectedin in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study.

  • Trabectedin is sold as Yondelis by Janssen, a Johnson & Johnson (NYSE: JNJ) company.

  • Also Read: Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies.

  • IMX-110 was compared against approved drugs used to treat STS in this study.

  • According to Meco et al., 2003 (trabectedin monotherapy treatment arm), trabectedin was dosed, and IMX-110 was administered at 2.0 mg/kg.

  • "We are excited to see continued evidence of IMX-110 anti-tumor activity versus approved therapies," said Ilya Rachman, CEO of ImmixBio. "We believe this is a preview of anti-tumor activity to be demonstrated in our two clinical trials to be kicked off in 2022: IMX-110 monotherapy and IMX-110 in combination with anti-PD-1 tislelizumab."

  • Price Action: IMMX shares are up 57.7% at $2.57 during the market session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting